Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients
暂无分享,去创建一个
Amalio Telenti | Hansjakob Furrer | Thierry Buclin | Olivia Keiser | A. Telenti | T. Buclin | J. Biollaz | H. Furrer | M. Rotger | L. Decosterd | O. Keiser | G. Bleiber | Sara Colombo | Margalida Rotger | S. Colombo | Jérôme Biollaz | Gabriela Bleiber | Belle L Lee | Laurent Décosterd | Belle L. Lee | Gabriela Bleiber
[1] S. Bandiera,et al. Constitutive androstane receptor and pregnane X receptor gene expression in human liver: interindividual variability and correlation with CYP2B6 mRNA levels. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[2] David A. Flockhart,et al. The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic Activity , 2003, Journal of Pharmacology and Experimental Therapeutics.
[3] H. Jinno,et al. Functional characterization of cytochrome P450 2B6 allelic variants. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[4] D. Waxman,et al. Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[5] P. Beaune,et al. Human CYP2B6: expression, inducibility and catalytic activities. , 1999, Pharmacogenetics.
[6] D. Mash,et al. Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain , 2003, Neuropharmacology.
[7] U. Hofmann,et al. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. , 2001, Pharmacogenetics.
[8] S. Ekins,et al. Further characterization of the expression in liver and catalytic activity of CYP2B6. , 1998, The Journal of pharmacology and experimental therapeutics.
[9] A. Telenti,et al. Efavirenz Plasma Levels Can Predict Treatment Failure and Central Nervous System Side Effects in Hiv-1-infected Patients , 2022 .
[10] R H Levy,et al. Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[11] T. Uchida,et al. Cytochrome P450 gene expression levels in peripheral blood mononuclear cells in comparison with the liver , 2004, Cancer science.
[12] S. Oka,et al. Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. , 2004, Biochemical and biophysical research communications.
[13] U. Yasar,et al. Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation , 2003, The Pharmacogenomics Journal.
[14] J. Reynes,et al. Long‐term assessment of neuropsychiatric adverse reactions associated with efavirenz , 2003, HIV medicine.
[15] Jacques Fellay,et al. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection , 2003, Clinical pharmacology and therapeutics.
[16] T. Kamataki,et al. A single nucleotide polymorphism of CYP2b6 found in Japanese enhances catalytic activity by autoactivation. , 2001, Biochemical and biophysical research communications.
[17] U. Gundert-Remy,et al. Immunochemical analysis of cytochrome P450 variability in human leukapheresed samples and its consequences for the risk assessment process. , 2003, Regulatory toxicology and pharmacology : RTP.